ERT and Bioclinica Become Clario
ERT announced that following its early Q2 merger with Bioclinica, the combined company is renamed Clario. Clario is a technology company that generates clinical evidence by fusing scientific knowledge and global scale into the endpoint technology platform.
Only Clario can deliver Trial Anywhere, the ability to execute decentralized, hybrid and site-based clinical trials by deploying technology while maintaining the precision and reliability of evidence.
Since 1990, Clario has completed more than 19,000 clinical trials and contributed to 870 regulatory approvals. Between 2019 and 2020 alone, Clario supported 70% of all Federal and Drug Administration (FDA) approvals.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
